Our fourth quarter results was driven largely by a 69 basis point sequential expansion in gross margin as we leveraged a modest increase in sales to the gross profit line. As reflected in our gross margin expansion, the wave of important generic drugs with patent exclusivity has begun to take form, and we remain very excited about the opportunity generic drug introductions represent for both Omnicare and its customers.

Read the rest of this transcript for free on seekingalpha.com

If you liked this article you might like

New Lifetime High Today: Omnicare (OCR)

Omnicare (OCR) Hits New Lifetime High Today

Omnicare (OCR) Hits New Lifetime High Today

Don't Miss Today's Strong And Under The Radar Stock: Omnicare (OCR)

Barbarian At The Gate: Omnicare (OCR)